Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -37.50% and 59.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer...
/PRNewswire/ -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo...
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 25% and 32.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
/PRNewswire/ -- Selecta Biosciences, Inc. (NASDAQ: SELB, President and CEO: Carsten Brunn, Ph.D., "Selecta"), and Astellas Pharma Inc. (TSE: 4503, President...
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -200% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...
ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 8.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Elevance Health (ELV) devises suitable Medicare Advantage plans containing supplemental benefits, which consumers can avail in the 2023 Annual Enrollment Period.
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 300% and 83.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I...